Cargando…

Radiotherapy plus cetuximab for locally advanced squamous cell head and neck cancer in patients with cisplatin-ineligible renal dysfunction: A retrospective study

Clinical trials have not fully demonstrated the efficacy and safety of radiotherapy plus cetuximab for locally advanced squamous cell head and neck cancer (LA-SCCHN) in patients with cisplatin-ineligible renal dysfunction. Patients who received radiotherapy plus cetuximab for LA-SCCHN at Chiba Unive...

Descripción completa

Detalles Bibliográficos
Autores principales:	Imai, Chiaki, Saeki, Hiromi, Yamamoto, Kohei, Ichikawa, Ayano, Arai, Makoto, Tawada, Akinobu, Suzuki, Takaaki, Takiguchi, Yuichi, Hanazawa, Toyoyuki, Ishii, Itsuko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9258593/ https://www.ncbi.nlm.nih.gov/pubmed/35836484 http://dx.doi.org/10.3892/ol.2022.13271

Ejemplares similares

Sequential administration of PD‑1 inhibitor and cetuximab causes pneumonia
por: Arai, Makoto, et al.
Publicado: (2023)

Initial experience of radiotherapy plus cetuximab for Japanese head and neck cancer patients
por: Kurokawa, Marie, et al.
Publicado: (2015)

Cetuximab for Immunotherapy-Refractory/Ineligible Cutaneous Squamous Cell Carcinoma
por: Marin-Acevedo, Julian A., et al.
Publicado: (2023)

Current status of medical oncology in Japan and changes over the most recent 7-year period: results of a questionnaire sent to designated cancer care hospitals
por: Arai, Makoto, et al.
Publicado: (2021)

Risk factors associated with ineligibility of adjuvant cisplatin-based chemotherapy after nephroureterectomy
por: Shao, I-Hung, et al.
Publicado: (2014)

Nelarabine-induced rhabdomyolysis in a patient with T-cell acute lymphoblastic leukemia: a case report
por: Utsumi, Akari, et al.
Publicado: (2022)

Cisplatin Plus Cetuximab Inhibits Cisplatin-Resistant Human Oral Squamous Cell Carcinoma Cell Migration and Proliferation but Does Not Enhance Apoptosis
por: Choi, Hyeong Sim, et al.
Publicado: (2021)

Contrasting functions of the epithelial-stromal interaction 1 gene, in human oral and lung squamous cell cancers
por: Fan, Mengmeng, et al.
Publicado: (2022)

Weekly Paclitaxel, Carboplatin, and Cetuximab as First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma for Patients Ineligible to Cisplatin-Based Chemotherapy: A Retrospective Monocentric Study in 60 Patients
por: Carinato, Hélène, et al.
Publicado: (2021)

Venetoclax plus low-dose cytarabine in Japanese patients with untreated acute myeloid leukaemia ineligible for intensive chemotherapy
por: Yamauchi, Takahiro, et al.
Publicado: (2021)

The Ineligibility of Antipyrin in Pneumonia
Publicado: (1886)

Long-Term Survival of Patients With Chemotherapy-Naïve Metastatic Nasopharyngeal Carcinoma Receiving Cetuximab Plus Docetaxel and Cisplatin Regimen
por: Zhang, Mengping, et al.
Publicado: (2020)

Rapid Response to Pembrolizumab in a Chemo-Refractory Testicular Germ Cell Cancer with Microsatellite Instability-High
por: Kawai, Koji, et al.
Publicado: (2021)

Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy
por: Yamamoto, Kazuhito, et al.
Publicado: (2021)

Modified biweekly cisplatin, docetaxel plus cetuximab (TPEx) as first-line treatment for patients with recurrent/metastatic head and neck cancer
por: Fuchs, Hannah, et al.
Publicado: (2018)

Randomized phase II trial of S‐1 plus cisplatin or docetaxel plus cisplatin with concurrent thoracic radiotherapy for inoperable stage III non‐small cell lung cancer
por: Shimokawa, Tsuneo, et al.
Publicado: (2020)

The efficacy and safety of first-line treatment in cisplatin-ineligible advanced upper tract urothelial carcinoma patients: a comparison of PD-1 inhibitor and carboplatin plus gemcitabine chemotherapy
por: Huang, Jiwei, et al.
Publicado: (2022)

A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naïve, cisplatin-ineligible urothelial cancer
por: Galffy, G., et al.
Publicado: (2023)

Efficacy and Safety of Cetuximab Plus Cisplatin Alone or in Combination With Paclitaxel in Patients With Head and Neck Squamous Cell Carcinoma: A Randomized Trial
por: Zheng, Yanqing, et al.
Publicado: (2021)

Paclitaxel Plus Cetuximab as Induction Chemotherapy for Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Unfit for Cisplatin-Based Chemotherapy
por: Marín-Jiménez, Juan A., et al.
Publicado: (2022)

FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin‐Containing Chemotherapy
por: Suzman, Daniel L., et al.
Publicado: (2018)

Cusatuzumab plus azacitidine in Japanese patients with newly diagnosed acute myeloid leukemia ineligible for intensive treatment
por: Ikezoe, Takayuki, et al.
Publicado: (2022)

Correction to: Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy
Publicado: (2023)

Analysis of the variable factors affecting changes in the blood concentration of cyclosporine before and after transfusion of red blood cell concentrate
por: Uchida, Masashi, et al.
Publicado: (2022)

The Cost-Effectiveness Analysis of Transplant-Ineligible Myeloma Patients with Bortezomib plus Thalidomide plus Dexamethasone (VTD) or Bortezomib plus Melphalan plus Prednisolone (VMP) Treatment in Southern Taiwan
por: Du, Jeng-Shiun, et al.
Publicado: (2022)

Severe skin reaction secondary to concomitant radiotherapy plus cetuximab
por: Berger, Bernhard, et al.
Publicado: (2008)

Retracted: “Efficacy and Safety of Cetuximab Plus Cisplatin Alone or in Combination With Paclitaxel in Patients With Head and Neck Squamous Cell Carcinoma: A Randomized Trial”
Publicado: (2023)

Phase II Clinical and Translational Study of Everolimus ± Paclitaxel as First-Line Therapy in Cisplatin-Ineligible Advanced Urothelial Carcinoma
por: Jun, Tomi, et al.
Publicado: (2022)

Azacytidine plus olaparib for relapsed acute myeloid leukaemia, ineligible for intensive chemotherapy, diagnosed with a synchronous malignancy
por: Iluta, Sabina, et al.
Publicado: (2021)

Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA
por: Facon, Thierry, et al.
Publicado: (2022)

Reproduction of the Antitumor Effect of Cisplatin and Cetuximab Using a Three-dimensional Spheroid Model in Oral Cancer
por: Ono, Kisho, et al.
Publicado: (2022)

microRNA-1/133a and microRNA-206/133b clusters: Dysregulation and functional roles in human cancers
por: Nohata, Nijiro, et al.
Publicado: (2012)

A Phase II Clinical Trial of Concurrent Helical Tomotherapy plus Cetuximab Followed by Adjuvant Chemotherapy with Cisplatin and Docetaxel for Locally Advanced Nasopharyngeal Carcinoma
por: Zhang, Xinxin, et al.
Publicado: (2016)

Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial
por: Caponigro, Francesco, et al.
Publicado: (2016)

Safety and short-term efficacy of preoperative FOLFOX therapy in patients with resectable esophageal squamous cell carcinoma who are ineligible for cisplatin
por: Kadono, Toru, et al.
Publicado: (2022)

Cetuximab plus FOLFOX for Patients with Metastatic Colorectal Cancer with Poor Performance Status and/or Severe Tumor-Related Complications
por: Shitara, Kohei, et al.
Publicado: (2010)

Removal of ineligible outcome cases reduces confounding
por: Walker, Alexander M, et al.
Publicado: (2018)

Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin
por: Kanda, Tatsuo, et al.
Publicado: (2017)

Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status
por: Grivas, Petros, et al.
Publicado: (2020)

Use of Cetuximab in Combination with Cisplatin and Adjuvant Pelvic Radiation for Stage IIIB Vulvar Carcinoma
por: Bergstrom, Jennifer, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_mj8f8j2av2hvf64toodgf2j6ic